B
ICPT

Barings’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Barings’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-3,380
Closed -$800K – 990
2014
Q2 		$800K Buy
+3,380
New +$891K 0.02% 574

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Barings's ICPT Position: Q3 2014 in Review

Barings sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2014, closing a stake of 3,380 shares — an estimated $800K sold.

Barings first reported a position in ICPT in Q2 2014 and held it in 1 quarter. The position peaked at $800K in Q2 2014. 181 funds tracked by Wall St. Rank hold ICPT as of Q3 2014.

  • Barings reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Barings sold 3,380 Intercept Pharmaceuticals, Inc. shares in Q3 2014, an estimated $800K.
  • Barings first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
  • Barings's Intercept Pharmaceuticals, Inc. position peaked at $800K in Q2 2014.
  • 181 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2014.

Based on Barings's 13F filing for Q3 2014, filed 14 Nov 2014.